12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Latuda lurasidone regulatory update

Dainippon Sumitomo and partner Takeda said EMA accepted for review an MAA for lurasidone to treat schizophrenia. Takeda has exclusive rights from Dainippon to commercialize the product for schizophrenia and bipolar disorder in the...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >